Figure 4

Co-treatment of HeLa cells with BafA and additional autophagosome-lysosome fusion inhibitors. (A) Representative Western blots for LC3, p62/SQSTM1 and actin (top) and quantification (n = 3; mean ± SEM) of HeLa cells co-treated with either DMSO (left) or 2.5 nM BafA (right) and a dose range (0.3–30 µM) of CQ for 24 h. Statistics: one sample t-test, compared to 100% control (either DMSO only or 2.5 nM BafA only). (B) Representative Western blots for LC3, p62/SQSTM1 and actin (top) and quantification (n = 3; mean ± SEM) of HeLa cells co-treated with either DMSO (left) or 2.5 nM BafA (right) and a dose range (63 pM–1 nM) of ConA for 24 h. Statistics: one sample t-test, compared to 100% control (either DMSO only or 2.5 nM BafA only).